Male Factor is Solely Responsible in An Estimated 20% of Infertile Couples

Infertility refers to the inability of a man or woman in conceiving a child. Statistics by the American Urology Association show that a male factor is solely responsible in an estimated 20% of infertile couples. The Centers for Disease Control and Prevention (CDC), in an evaluation of a 2002 National Survey of Family Growth, found that 3.3-4.7 million men in the United States younger than 45 years reported to visiting a fertility doctor during their lifetime. Of these, 18% men were diagnosed with an infertility problem such as sperm or semen problems (14%) and varicocele (6%).
 
The global male infertility treatment market is driven by a host of factors such as rise in obesity, increasing consumption of drugs, alcohol, surge in smoking population, change in lifestyle, growing incidence of infertility cases, and different environmental factors. 
 
The North America region is the largest market for male infertility treatment in terms of revenue owing to greater awareness, higher chances of lifestyle disorders, and improved reimbursement facilities for the treatment of male infertility. Availability of well-established healthcare infrastructure and increasing medical tourism can also aids the growth of the male infertility treatment market in North America. 
 
Asia Pacific is emerging as a strong contender in the global male infertility treatment market owing to drastic lifestyle changes and rising cases of infertility. Emotional stress is also a major cause for male infertility and according to the global Organization for Stress, the highest stress rate was found in China. The organization reveals that six in 10 individuals around the world suffer from stress at the work place. The Asia Pacific market for male infertility treatment is also fueled by increasing healthcare expenditure and a large section of the male population rapidly overcoming the guilt, shame, and social taboo surrounding male infertility. 
 
Some of the leading players operating in the global male infertility treatment market are Andrology Solutions, Access Pharmaceuticals, Inc., Cordex Pharma, Inc., SCSA diagnostics, Pantarhei Bioscience B, ASKA Pharmaceutical Co. Ltd, ZydusCadila Healthcare Limited, Halotech DNA SL, Intas Pharmaceuticals Ltd., EMD Serona Inc., and Merck Serono.